Pharmacovigilance applied to social networks

Pharmacovigilance applied to social network refers to the collection and monitoring of any report of adverse reactions to drugs or other safety information that patients, health professionals and citizens in general can report in the social networks. This activity is born out of the need to include also digital platforms among the usually controlled sources and reporting channels, used by many to share their daily experience.
What is pharmacovigilance and why it is important to apply it to social networks
Pharmacovigilance is a set of activities dedicated to identify, assess, understand and prevent adverse reactions or any other safety issue linked to medicines. Traditionally, these reports come via email, phone or dedicated portals. Today, social networks represent an additional channel to watch.
In fact, many people leave comments or publish posts where they report important information on medicinal products, including any issue they detected following their use. It is therefore important to identify and promptly manage such pharmacovigilance reports, in order to collect safety information that would otherwise risk to be lost in the daily flow of online conversations.
The role of the MA Holder in the EU
In the EU, the close monitoring of social networks is a task of the Marketing Authorisation (MA) Holder of the drug, who is bound, in accordance with the Good Pharmacovigilance Practices (GVPs), to regularly check the internet and the digital media (including social platforms) they manage or are responsible for, in order to identify potential reports of suspected adverse reactions. A digital media (e.g. a social channel, a website, etc.) is considered as sponsored by a MA Holder if it is owned, funded and/or controlled by them.
How to manage pharmacovigilance reports in the social networks
The monitoring of social channels for the identification of reports of adverse reactions to drugs or other safety information should be performed on a regular basis, to allow prompt actions, for instance in case of relevant safety information affecting public health and/or reports of serious adverse reactions. As described in the Good Pharmacovigilance Practices (GVPs), the screening frequency should allow to share potential valid adverse reactions to the Competent Authorities within the timelines provided for by the regulations, to be calculated based on the date of publication of the information in the internet site/digital media. To this end, it is important to have a Standard Operating Procedure (SOP) describing in detail the process, the monitoring responsible figures, the flows to be followed in case of identification of pharmacovigilance information, and also how to collect the evidence to demonstrate that the control was carried out.
What is meant by ‘valid reporting’
According to the Good Pharmacovigilance Practices (GVPs), only reports of adverse reactions considered as valid can be shared with the Competent Authorities. Four minimum criteria must be met to consider a report as valid:
- One or more identifiable reporters
- An identifiable patient
- One or more suspected substances/medicines
- One or more suspected adverse reactions
Promoting the reporting of adverse reactions
To encourage patients and health professionals to report adverse reactions, also via the social network, several initiatives were created, including the annual #MedSafetyWeek, during which the Uppsala Monitoring Centre cooperates with medicine regulatory Authorities, pharmacovigilance national centres, and international organisations all over the world, to promote the reporting of side effects. The 2025 campaign will celebrate the 10th anniversary of the #MedSafetyWeek, that will take place from 3 to 9 November and will focus on how everybody can contribute to make drugs safer. The monitoring of social networks to identify adverse reactions or safety issues concerning medicines has therefore become integral part of the pharmacovigilance processes, that pharmaceutical Companies are bound to carry out thoroughly and systematically, to further ensure safety of the drugs on the market.
Previous Post
Next Post